Search research articles
Contact Us
Filters
Showing results (81-90 of 209) with videos related to
Page
of 21
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
November 26, 2023
Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort
Eric Jonasch, Todd M Bauer, Kyriakos P Papadopoulos, et al.
Clinical Genitourinary Cancer
|
December 20, 2016
Small-Cell Carcinoma of the Bladder: 20-Year Single-Institution Retrospective Review
Kyungsuk Jung, Pooja Ghatalia, Samuel Litwin, et al.
Nature Medicine
|
April 23, 2021
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis
Toni K Choueiri, Todd M Bauer, Kyriakos P Papadopoulos, et al.
European Urology
|
November 6, 2024
First and Second-line Treatments in Metastatic Renal Cell Carcinoma
Regina Barragan-Carrillo, Eddy Saad, Renee-Maria Saliby, et al.
Nature Medicine
|
August 28, 2021
Author Correction: Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis
Toni K Choueiri, Todd M Bauer, Kyriakos P Papadopoulos, et al.
The Prostate
|
January 29, 2026
Phase II Randomized Study of MK-2206 and Bicalutamide in Prostate Cancer Patients With Rising PSA After Primary Therapy (ECOG-ACRIN E2809)
Anna C Ferrari, Yu-Hui Chen, Ronald Rodríguez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 21, 2020
Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma
Jean-François Martini, Elizabeth R Plimack, Toni K Choueiri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 10, 2018
Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer
Alicia K Morgans, Yu-Hui Chen, Christopher J Sweeney, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 7, 2021
Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial
Michael B Atkins, Elizabeth R Plimack, Igor Puzanov, et al.
The Oncologist
|
March 6, 2019
First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer
Aiwu Ruth He, Roger B Cohen, Crystal S Denlinger, et al.
Page
of 21
Search research articles
Search
Showing results (81-90 of 209) with videos related to
Sort By:
Page
of 21
European Journal of Cancer (Oxford, England : 1990)
|
November 26, 2023
Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort
Eric Jonasch, Todd M Bauer, Kyriakos P Papadopoulos, et al.
Clinical Genitourinary Cancer
|
December 20, 2016
Small-Cell Carcinoma of the Bladder: 20-Year Single-Institution Retrospective Review
Kyungsuk Jung, Pooja Ghatalia, Samuel Litwin, et al.
Nature Medicine
|
April 23, 2021
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis
Toni K Choueiri, Todd M Bauer, Kyriakos P Papadopoulos, et al.
European Urology
|
November 6, 2024
First and Second-line Treatments in Metastatic Renal Cell Carcinoma
Regina Barragan-Carrillo, Eddy Saad, Renee-Maria Saliby, et al.
Nature Medicine
|
August 28, 2021
Author Correction: Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis
Toni K Choueiri, Todd M Bauer, Kyriakos P Papadopoulos, et al.
The Prostate
|
January 29, 2026
Phase II Randomized Study of MK-2206 and Bicalutamide in Prostate Cancer Patients With Rising PSA After Primary Therapy (ECOG-ACRIN E2809)
Anna C Ferrari, Yu-Hui Chen, Ronald Rodríguez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 21, 2020
Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma
Jean-François Martini, Elizabeth R Plimack, Toni K Choueiri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 10, 2018
Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer
Alicia K Morgans, Yu-Hui Chen, Christopher J Sweeney, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 7, 2021
Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial
Michael B Atkins, Elizabeth R Plimack, Igor Puzanov, et al.
The Oncologist
|
March 6, 2019
First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer
Aiwu Ruth He, Roger B Cohen, Crystal S Denlinger, et al.
Page
of 21